Hims & Hers Health enters July with an unusual tension at its core: the stock has rallied 33% in a month while short sellers continue adding to what is already one of the largest short positions in healthcare services.
The short side of this story is genuinely extreme. Nearly 30% of the free float is sold short — 64.3 million shares as of June 30 — and that figure rose 7% across the past week alone. The acceleration began June 24, when short interest jumped from roughly 59 million to 64 million shares in two sessions. Yet borrow availability, which had sat at zero through much of June as the lending pool ran completely dry, has since loosened to around 15% — still tight by most standards, but a meaningful release valve compared to the near-total lock-up seen in early June. Cost to borrow has responded in kind, climbing 72% across the week to 1.48%, its highest reading since mid-May. The ORTEX short score, at 69.4 and a new high for the period tracked, reflects that the full constellation of short-side signals is pulling in the same direction.
Options traders are also growing more cautious, though from a low base. The put/call ratio jumped to 0.61 on Tuesday — more than three standard deviations above its 20-day mean of 0.55. That's well off the 52-week high of 1.52, so this is not outright fear, but the spike is notable given how consistently calm PCR had been through all of June. Calls still dominate the options market, but the balance shifted abruptly at week-end.
The Street, meanwhile, is scrambling to reprice after a month that clearly caught consensus off-guard. BofA lifted its target from $25 to $36 this morning while holding a Neutral rating — the same analyst cut the target twice through May. Canaccord raised to $40 and kept Buy. Barclays moved to $39 on June 18. The direction of travel is unambiguous: targets are climbing fast, but the majority of coverage remains at Neutral or Hold, leaving the consensus mean target at $28.35 — now below the stock's $34.67 close. That inversion, where the stock trades above the average analyst target, reflects how quickly the rally has overtaken Street models. The bull case centres on the Novo Nordisk partnership and subscriber growth momentum. Bears point to declining gross margins, operating expense creep, and what they see as dangerous concentration in the weight-loss compound franchise ahead of potential regulatory change.
Insiders have used the move to sell. The CFO sold just over $1.2 million in shares on June 15, and sold again on June 22. The COO and CTO both sold on June 17 at $31.50, and the Chief Medical Officer sold $830,000 worth at $35 on June 18. None of these are enormous as a percentage of the company, and all arrived alongside RSU award grants to the same executives, but the cluster of C-suite sales across eight days — right through the price spike — is a pattern worth noting. The 90-day insider net is technically positive at 14.6 million in value, but that is almost entirely RSU awards at zero cost; the open-market activity tells a more cautious story.
Earnings history adds context: when HIMS last reported on June 11, the stock fell 3.5% on the day but recovered strongly, gaining 28% over the following five sessions. The prior print in May triggered an 11% one-day drop and a 21% five-day decline. The next report is due August 3. With the stock trading above every major analyst target and short interest at 30% of float, the setup heading into that print is less about whether growth is real and more about whether the current valuation leaves any room for execution risk.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
